In this episode of Huberman Lab Essentials, my guest is Dr. Karl Deisseroth, M.D., Ph.D., a clinical psychiatrist and professor of bioengineering and of psychiatry and behavioral sciences at Stanford University.
We discuss his experiences as a clinician treating complex psychiatric conditions and his lab’s pioneering work in developing transformative therapies for mental illness. He explains the complexities of mental illness and how emerging technologies—such as optogenetics and brain-machine interfaces—could revolutionize care. We also explore promising new therapies, including psychedelics and MDMA, for conditions like depression and PTSD.
Read the episode show notes at hubermanlab.com.
Huberman Lab Essentials are short episodes focused on essential science and protocol takeaways from past full-length Huberman Lab episodes. Watch or listen to the full-length episode at hubermanlab.com.
Thank you to our sponsors
AG1: https://drinkag1.com/huberman
David: https://davidprotein.com/huberman
Eight Sleep: https://eightsleep.com/huberman
Timestamps
Karl Deisseroth; Neurology vs Psychiatry
Speech; Blood Test?; Seeking Help
Feelings, Jargon; Psychiatric Treatment
Sponsor: David
Future Treatment; Vagus Nerve Stimulation, Depression, Optogenetics
Brain-Machine Interfaces
Sponsor: Eight Sleep
ADHD Symptoms, Lifestyle, Technology
Psychedelics, Depression Treatment, Risks
Sponsor: AG1
MDMA (Ecstasy), Trauma & Post-Traumatic Stress Disorder (PTSD) Treatment
Projections: A Story of Human Emotions Book, Optimism
Learn more about your ad choices. Visit megaphone.fm/adchoices
